Affordable Access

deepdyve-link
Publisher Website

Cripto-1 expression in glioblastoma multiforme.

Authors
  • Pilgaard, Linda
  • Mortensen, Joachim Høg
  • Henriksen, Michael
  • Olesen, Pia
  • Sørensen, Preben
  • Laursen, Rene
  • Vyberg, Mogens
  • Agger, Ralf
  • Zachar, Vladimir
  • Moos, Torben
  • Duroux, Meg
Type
Published Article
Journal
Brain Pathology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Jul 01, 2014
Volume
24
Issue
4
Pages
360–370
Identifiers
DOI: 10.1111/bpa.12131
PMID: 24521322
Source
Medline
Keywords
License
Unknown

Abstract

Human glioblastoma multiforme (GBM) is an aggressive cancer with a very poor prognosis. Cripto-1 (CR-1) has a key regulatory role in embryogenesis, while in adult tissue re-expression of CR-1 has been correlated to malignant progression in solid cancers of non-neuronal origin. As CR-1 expression has yet to be described in cerebral cancer and CR-1 is regulated by signaling pathways dysregulated in GBM, we aimed to investigate CR-1 in the context of expression in GBM. The study was performed using enzyme-linked immunosorbent assay (ELISA), Western blotting, polymerase chain reaction (PCR) and immunohistochemistry to analyze the blood and tissue from 28 GBM and 4 low-grade glioma patients. Within the patient cohort, we found high CR-1 protein levels in blood plasma to significantly correlate with a shorter overall survival. We identified CR-1 in different areas of GBM tissue, including perivascular tumor cells, and in endothelial cells. Collectively, our data suggest that CR-1 could be a prognostic biomarker for GBM with the potential of being a therapeutic target.

Report this publication

Statistics

Seen <100 times